Shareholder Keith A. Goldan plans 3,410-share sale in Syndax (SNDX)

Rhea-AI Filing Summary

Syndax Pharmaceuticals shareholder files notice to sell shares. A person named Keith A. Goldan filed a Form 144 covering the planned sale of 3,410 shares of common stock through Fidelity Brokerage Services LLC on the NASDAQ, with an aggregate market value of 71,706.84 and 86,914,838 shares outstanding.

The shares to be sold were acquired as restricted stock vesting on 02/06/2026 from the issuer as compensation. The form also reports that during the past three months, this person sold 2,082 common shares on 02/06/2026 for gross proceeds of 42,931.05. The filer represents that they are not aware of undisclosed material adverse information about the company.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	3410	71706.84	86914838	02/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/06/2026	Restricted Stock Vesting	Issuer			3410	02/06/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Keith A. Goldan 730 Third Avenue 9th Floor New York NY 10017	Common	02/06/2026	2082	42931.05

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the SNDX Form 144 filed by Keith A. Goldan disclose?

The Form 144 discloses a planned sale of 3,410 shares of Syndax Pharmaceuticals common stock. The shares are to be sold through Fidelity Brokerage Services LLC on NASDAQ, following recent vesting of restricted stock received from the issuer as compensation.

How many SNDX shares are planned to be sold under this Form 144?

The notice covers a planned sale of 3,410 shares of Syndax Pharmaceuticals common stock. These shares have an aggregate market value of 71,706.84 and are to be sold on NASDAQ through Fidelity Brokerage Services LLC, according to the filing’s securities information table.

How were the SNDX shares in the Form 144 acquired?

The 3,410 shares were acquired on 02/06/2026 through restricted stock vesting from the issuer. The filing states the nature of the acquisition transaction as “Restricted Stock Vesting” and identifies the consideration as “Compensation” paid on the same date.

What prior SNDX share sales does the Form 144 report?

The filing reports that during the past three months, the person for whose account the shares are to be sold disposed of 2,082 common shares on 02/06/2026. Those sales generated gross proceeds of 42,931.05, as listed in the securities sold during the past three months table.

What representation does the seller make in the SNDX Form 144?

By signing the notice, the person for whose account the securities are to be sold represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed, as stated in the form’s signature section.

What is the total number of SNDX shares outstanding referenced in the Form 144?

The Form 144 states that 86,914,838 shares of Syndax Pharmaceuticals common stock are outstanding. This figure appears in the securities information table and serves as a baseline context for the 3,410 shares covered by the planned sale notice.